Business

Acorda Therapeutics has announced that it will acquire inhaled drug developer Civitas Therapeutics, including rights to the ARCUS inhalation platform, for $525 million in cash. The deal includes worldwide rights to Civitas’s lead candidate, CVT-301… Read more . . .

Dr. Reddy’s Laboratories have announced that the company has launched generic levalbuterol inhalation solution in the US as of September 23, 2014. The generic version of Sunovion’s Xopenex is available in 0.31 mg /3 mL,… Read more . . .

Almac subsidiary Galen Ltd will pay Medical Developments International (MVP) approximately A$650,000 (~US$587,000) up front for a license to market and distribute MVP’s Penthrox inhaled methoxyflurane in the UK and Ireland. The deal also includes… Read more . . .

In its most recent interim report, Verona Pharma says that it raised over £14 million pounds earlier this year which will allow it to continue development of its RPL554, an inhaled PDE3/PDE4 inhibitor, for the… Read more . . .

Prosonix has announced that a consortium of inhaled medicine and respiratory disease researchers with funding from the Biomedical Catalyst “has confirmed the potential of its Multi-component Particle (MCP) Technology for creating novel inhaled, dual and… Read more . . .

Cipla has announced that it has entered into a distribution agreement with S&D Pharma in the Czech Republic and Slovakia in which S&D will distribute Cipla products. The deal includes distribution “in the near future,… Read more . . .

Pfizer UK has announced that it has signed an exclusive agreement with Novartis to market the Ultibro Breezhaler indacaterol/glycopyrronium DPI and the Seebri Breezhaler glycopyrronium DPI in the UK for the treatment of COPD. Seebri… Read more . . .

Teva has announced that the UK High Court has invalidated AstraZeneca’s patent titled “Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma” (EP 1,085,877), which… Read more . . .